Trump Nominates Dr. Heidi Overton to Lead the FDA

President Trump has picked a familiar face from inside his own White House to run the Food and Drug Administration: Dr. Heidi Overton, currently deputy director of the Domestic Policy Council. If confirmed, she'd take the reins of one of the most powerful health agencies in the country — the one that decides what drugs, vaccines, and food products get to market.

Who Is Heidi Overton? Overton isn't a Washington outsider getting parachuted in. She's been working directly alongside Trump, RFK Jr., and Dr. Oz on what the administration calls its health agenda, focusing heavily on lowering prescription drug prices. Before joining the White House, she was vice chair and chief policy officer at the America First Policy Institute's Center for a Healthy America — a conservative nonprofit previously run by now-Agriculture Secretary Brooke Rollins. She holds a doctorate from Johns Hopkins, giving her real scientific credentials to pair with her policy resume.

Why This Pick Is Getting Attention Overton has publicly backed rolling back the childhood immunization schedule, framing it as "restoring vaccination authority to parents" and pushing for "gold-standard science" in how vaccine recommendations get made. She's also anti-abortion. Both stances put her squarely in line with the administration's broader push to remake federal health policy — but they're also the kind of positions that could make her Senate confirmation a fight, especially with medical groups watching vaccine policy shifts closely.

What Trump Said In his announcement, Trump called Overton a "ROCKSTAR" in his administration and credited her with helping deliver what he described as the "MOST TRANSFORMATIVE Health Agenda in History." He said he wants her running the FDA to keep the U.S. as the "WORLD LEADER" in scientific discovery and cures — signaling he expects her to keep pushing the same priorities from a much bigger chair.

What Happens Next Overton still needs Senate confirmation before she can officially take over as FDA commissioner. Given her ties to vaccine policy changes already underway — including the executive order reviewing childhood vaccine recommendations she helped shepherd earlier this month — expect confirmation hearings to zero in on where she plans to take the agency's stance on immunizations, drug approvals, and pricing reform.

Why This Matters for You The FDA touches nearly everything in your medicine cabinet, from the vaccines your kids get to how fast new drugs reach pharmacy shelves. A leadership change this significant could reshape approval timelines, vaccine guidance, and drug pricing policy — all things that hit regular people's health decisions and wallets directly.